Literature DB >> 19748998

Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

Kurt R Stenmark1, Barbara Meyrick, Nazzareno Galie, Wolter J Mooi, Ivan F McMurtry.   

Abstract

At present, six groups of chronic pulmonary hypertension (PH) are described. Among these, group 1 (and 1') comprises a group of diverse diseases termed pulmonary arterial hypertension (PAH) that have several pathophysiological, histological, and prognostic features in common. PAH is a particularly severe and progressive form of PH that frequently leads to right heart failure and premature death. The diagnosis of PAH must include a series of defined clinical parameters, which extend beyond mere elevations in pulmonary arterial pressures and include precapillary PH, pulmonary hypertensive arteriopathy (usually with plexiform lesions), slow clinical onset (months or years), and a chronic time course (years) characterized by progressive deterioration. What appears to distinguish PAH from other forms of PH is the severity of the arteriopathy observed, the defining characteristic of which is "plexogenic arteriopathy." The pathogenesis of this arteriopathy remains unclear despite intense investigation in a variety of animal model systems. The most commonly used animal models ("classic" models) are rodents exposed to either hypoxia or monocrotaline. Newer models, which involve modification of classic approaches, have been developed that exhibit more severe PH and vascular lesions, which include neointimal proliferation and occlusion of small vessels. In addition, genetically manipulated mice have been generated that have provided insight into the role of specific molecules in the pulmonary hypertensive process. Unfortunately, at present, there is no perfect preclinical model that completely recapitulates human PAH. All models, however, have provided and will continue to provide invaluable insight into the numerous pathways that contribute to the development and maintenance of PH. Use of both classic and newly developed animal models will allow continued rigorous testing of new hypotheses regarding pathogenesis and treatment. This review highlights progress that has been made in animal modeling of this important human condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748998     DOI: 10.1152/ajplung.00217.2009

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  316 in total

1.  Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis.

Authors:  Alexander M S Barron; Julio C Mantero; Jonathan D Ho; Banafsheh Nazari; Katharine L Horback; Jag Bhawan; Robert Lafyatis; Christina Lam; Jeffrey L Browning
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

Review 2.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

3.  Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling.

Authors:  Zachary Van Rheen; Cheryl Fattman; Shannon Domarski; Susan Majka; Dwight Klemm; Kurt R Stenmark; Eva Nozik-Grayck
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-10       Impact factor: 6.914

4.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

5.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

6.  Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism.

Authors:  Paul W Buehler; Jin Hyen Baek; Christina Lisk; Ian Connor; Tim Sullivan; Douglas Kominsky; Susan Majka; Kurt R Stenmark; Eva Nozik-Grayck; Joe Bonaventura; David C Irwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-22       Impact factor: 5.464

Review 7.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

8.  Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

Authors:  Rebecca R Vanderpool; Ah Ram Kim; Robert Molthen; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2010-11-18

9.  Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Authors:  Helen Christou; Hannes Hudalla; Zoe Michael; Evgenia J Filatava; Jun Li; Minglin Zhu; Jose S Possomato-Vieira; Carlos Dias-Junior; Stella Kourembanas; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2017-12-06       Impact factor: 4.030

10.  Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension.

Authors:  Abigail S Forrest; Talia C Joyce; Marissa L Huebner; Ramon J Ayon; Michael Wiwchar; John Joyce; Natalie Freitas; Alison J Davis; Linda Ye; Dayue D Duan; Cherie A Singer; Maria L Valencik; Iain A Greenwood; Normand Leblanc
Journal:  Am J Physiol Cell Physiol       Date:  2012-10-03       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.